The CCK‐8 assay indicated that the inhibitor of DDX3X (RK‐33) decreased the proliferation of DLBCL cell lines having TP53‐DDX3X co‐mutations. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.